Industries de la santé

Pluristem Announces Encouraging Six-Month Follow-up Results of its Phase I Critical Limb Ischemia Clinical Trials

HAIFA, ISRAEL, April 13, 2011 -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR;), today announced that following completion of three and six month clinical follow-up, data from its two open-label, dose-escalation, Phase I clinical trials conducted in the US and...

Résultats préliminaires de phase I/II dans l’indication du lupus Néovacs® valide un second candidat-médicament : l’IFNα-Kinoïde


Paris, le 8 avril 2011 – Néovacs® (Alternext Paris : ALNEV), entreprise de biotechnologie spécialisée dans le domaine de l’immunothérapie active des maladies auto‐immunes, inflammatoires et cancéreuses publie les résultats préliminaires de...

Pourquoi la France veut-elle interdire l'implantation des banques privées de cellules souches ?






Après avoir été adopté en première lecture par l'Assemblée Nationale, le projet de loi de Bioéthique est examiné au Sénat ce début avril. Avec lui, le débat autour de la conservation du sang de cordon ombilical - et par conséquent de l'utilisation de ces cellules à des fins...

Microfluidics to Donate LV1 Low Volume Microfluidizer® Processor to Innovative University Research Lab

Nanomaterials Processor Now Features Enhanced Temperature Control Options






March 17, 2011 - Newton, MA -To celebrate the one-year anniversary of its official launch in 2010, Microfluidics today announced a promotion to donate an LV1 Low Volume Microfluidizer processor to a...

Pluristem Therapeutics and NYU Medical Center Partner to Study Use of PLX Cells in Treatment of Diabetic Foot Ulcers










HAIFA, ISRAEL , March 15, 2011 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE:PLTR) and New York University (NYU) Medical Center today announced the formation of a partnership to study the use of Pluristem’s proprietary placenta-derived PLX cells for the...

Delivery of Drugs and Nutrients


Thursday, March 10, 2011 Register for our complimentary webinar:

* 10-11am ET session (convert time zone)* Or 2-3pm ET session
* Can't make it? Request a recording instead

Microfluidics is honored to present  guest speaker Robert Nicolosi, Ph.D., M.S., CNS, Professor and Director of the Center for Health & Disease Research at the University of...

Positive Pre-Clinical Data From Muscle Injury Study Moves Pluristem Toward Second Multi-Billion Dollar Clinical IndicationResearch Conducted at Berlin-Brandenburg Center for Regenerative Therapies and Charite University of Medicine Offers New Potentially Promising Cell Treatment for the Muscle Injury Market

HAIFA , Israel , March 1, 2011 -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI)...

Vers une nouvelle approche clinique dans la maladie de Crohn :
Les résultats de l’étude de phase I/II démontrent le potentiel du TNF-Kinoide dans le traitement de cette pathologie inflammatoire des intestins.
Dans le cadre du Congrès Européen ECCO (European Crohn’s and Colitis Organisation), Néovacs® présente les résultats de l’étude TNF-K-001 qui confirment clairement...

Globally Recognized Quality Management System Assures Customers That Appropriate Systems Are In Place To Meet specialized Needs

February 10, 2011 - Newton, MA - Microfluidics International Corporation (OTCBB:MFLU) today announced that its Quality Management System has achieved ISO 9001:2008 certification.

The certification verifies that Microfluidics has effectively applied the ISO 9001...

Vitrines Sociétés

Voir toutes les vitrines